Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Hervé Avet-Loiseau, Tineke Casneuf, Christopher Chiu, PhD, Jacob P. Laubach, MD, Je-Jung Lee, Philippe Moreau, Torben Plesner, Professor, Hareth Nahi, Nushmia Z Khokhar, Ming Qi, Jordan Schecter, Victoria Carlton, PhD, Xiang Qin, Kevin Liu, Kaida Wu, MD PhD, Sen H. Zhuang, MD, PhD, Tahamtan Ahmadi, MD, A. Kate Sasser, PhD, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 246.

https://doi.org/10.1182/blood.V128.22.246.246

Published: 2016

Journal Articles

Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.

Gabriele Buda, M.D., Deborah Ricci, Ph.D., Nadine Cohen, Ph.D., Reyna Favis, Ph.D., C. Chris Huang, Ph.D., Wayne Rackoff, M.D., Sen H. Zhuang, M.D., Ph.D., Jean Luc Harrouseau, M.D., Pieter Sonneveld, M.D., Ph.D., Joan Blade, M.D., Robert Z. Orlowski, M.D., Ph.D.

Blood (2009) 114 (22): 109.

https://doi.org/10.1182/blood.V114.22.109.109

Published: 2009

Journal Articles

The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.

Joan Blade, MD, Jesus San Miguel, MD, Arnon Nagler, MD, MSc, Pieter Sonneveld, MD, PhD, Andrew Spencer, DM, Tadeusz Robak, MD, PhD, Kathleen Hennessey, PharmD, Suneel D. Mundle, PhD, Sen H. Zhuang, MD, PhD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD

Blood (2007) 110 (11): 410.

https://doi.org/10.1182/blood.V110.11.410.410

Published: 2007

Journal Articles

Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.

Heather J. Sutherland, MD, PhD, Joan Blade, MD, Jesus San Miguel, MD, Arnon Nagler, MD, MSc, Pieter Sonneveld, MD, PhD, Andrew Spencer, DM, Tadeusz Robak, MD, PhD, Wane O’Neal, PharmD, Suneel D. Mundle, PhD, Sen H. Zhuang, MD, PhD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD

Blood (2007) 110 (11): 2740.

https://doi.org/10.1182/blood.V110.11.2740.2740

Published: 2007

Journal Articles

The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study.

Robert Z. Orlowski, MD, PhD, Sen H. Zhuang, MD, PhD, Trilok Parekh, PhD, Liang Xiu, PhD, Jean-Luc Harousseau, MD, the DOXIL-MMY-3001 Study Investigators

Blood (2006) 108 (11): 404.

https://doi.org/10.1182/blood.V108.11.404.404

Published: 2006

Journal Articles

Association of the p85 regulatory subunit of phosphatidylinositol 3- kinase with an essential erythropoietin receptor subdomain

TC He, H Zhuang, N Jiang, MD Waterfield, DM Wojchowski

Blood (1993) 82 (12): 3530–3538.

https://doi.org/10.1182/blood.V82.12.3530.3530

Published: 1993

NARROW

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.

The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.

Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.

The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study.

Association of the p85 regulatory subunit of phosphatidylinositol 3- kinase with an essential erythropoietin receptor subdomain

Email alerts

ASH Publications

American Society of Hematology

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.

The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.

Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.

The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study.

Association of the p85 regulatory subunit of phosphatidylinositol 3- kinase with an essential erythropoietin receptor subdomain

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only